clinical trial · NCT07217678
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
University of Miami·phase4·recruiting·n = 20
GlaucomaOpen-Angle GlaucomaOcular HypertensionGlaucoma SuspectDurysta, Bimatoprost Intracameral Implant 10 µg
brief summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
started
Feb 9, 2026
primary completion
Jan 31, 2028
completion
Jan 31, 2028
last updated
Mar 5, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol